4-Panel Drug Test (Strip) (Any Drug Combination) (DTS292)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Sample
urine
Intended Use
All of DOA Panel Test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of drug substances in human urine specimens. This assay may be used in the point of care setting. Below is a list of cut-off concentrations for each drug using our test.
Storage
The test device should be stored at 2 to 30°C and will be effective until the expiration date stated on the package. The product is humidity-sensitive and should be used immediately after being open. Any improperly sealed product should be discarded.
Sensitivity
The cut-off concentrations (sensitivity level) of DOA panel test are determined to be: AMP 1000 ng/ml, BAR, 300 ng/ml, BZO 300 ng/ml, BUP 10 ng/ml, COC 300 ng/ml, EDDP 100 ng/ml, MDMA 500 ng/ml, MTD 300 ng/ml, MET 1000 ng/ml, OPI 300 ng/ml, OPI II 2000 ng/ml, OXY 100 ng/ml, PCP 25 ng/ml, TCA 1000 ng/ml and THC 50 ng/ml.

Citations


Have you cited DTS292 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Fungal infections in humans: the silent crisis

MICROBIAL CELL

Authors: Kainz, Katharina; Bauer, Maria A.; Madeo, Frank; Carmona-Gutierrez, Didac

Annually, over 150 million severe cases of fungal infections occur worldwide, resulting in approximately 1.7 million deaths per year. Alarmingly, these numbers are continuously on the rise with a number of social and medical developments during the past decades that have abetted the spread of fungal infections. Additionally, the long-term therapeutic application and prophylactic use of antifungal drugs in high-risk patients have promoted the emergence of (multi)drug-resistant fungi, including the extremely virulent strain Candida auris. Hence, fungal infections are already a global threat that is becoming increasingly severe. In this article, we underline the importance of more and effective research to counteract fungal infections and their consequences.

Using Ex Vivo Porcine Jejunum to Identify Membrane Transporter Substrates: A Screening Tool for Early-Stage Drug Development

BIOMEDICINES

Authors: Arnold, Yvonne E.; Kalia, Yogeshvar N.

Robust, predictive ex vivo/in vitro models to study intestinal drug absorption by passive and active transport mechanisms are scarce. Membrane transporters can significantly impact drug uptake and transporter-mediated drug-drug interactions can play a pivotal role in determining the drug safety profile. Here, the presence and activity of seven clinically relevant apical/basolateral drug transporters found in human jejunum were tested using ex vivo porcine intestine in a Ussing chamber system. Experiments using known substrates of peptide transporter 1 (PEPT1), organic anion transporting polypeptide (OATP2B1), organic cation transporter 1 (OCT1), P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), multi drug resistance-associated protein 2 and 3 (MRP2 and MRP3), in the absence and presence of potent inhibitors, showed that there was a statistically significant change in apparent intestinal permeabilityP(app,pig)(cm/s) in the presence of the corresponding inhibitor. For MRP2, a transporter reportedly present at relatively low concentration, althoughP(app,pig)did not significantly change in the presence of the inhibitor, substrate deposition (Q(DEP)) in the intestinal tissue was significantly increased. The activity of the seven transport proteins was successfully demonstrated and the results provided insight into their apical/basolateral localization. In conclusion, the results suggest that studies using the porcine intestine/Ussing chamber system, which could easily be integrated into the drug development process, might enable the early-stage identification of new molecular entities that are substrates of membrane transporters.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket